Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Lymphoma Clinical Trials

Review the lymphoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 518

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 399 locations
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Status: Active
Location: 287 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 196 locations
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients with Peripheral T-cell Lymphoma who Achieved a Complete Response at the End of the Initial Chemotherapy
Status: Active
Location: 144 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 129 locations
A Phase 2 Study Adding the Drug Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment
Status: Active
Location: 127 locations
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Active
Location: 134 locations
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients with Relapsed and/or Refractory Aggressive B-cell Lymphoma
Status: Active
Location: 112 locations
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 100 locations
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status: Active
Location: 90 locations
Adding Pirtobrutinib to the Usual Treatment for People with Newly Diagnosed Richter Transformation, The PIRAMID Trial
Status: Active
Location: 62 locations
Testing Mosunetuzumab Alone, with Zanubrutinib, or with Polatuzumab Vedotin for Treating Marginal Zone Lymphoma that Came Back or Didn’t Get Better with Treatment
Status: Active
Location: 37 locations
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Status: Active
Location: 34 locations
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Status: Active
Location: 31 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 30 locations
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Status: Active
Location: 28 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 30 locations
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Status: Active
Location: 24 locations
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Status: Active
Location: 20 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 20 locations
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Status: Active
Location: 19 locations
DALY II USA/ MB-CART2019.1 for DLBCL
Status: Active
Location: 18 locations
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Status: Active
Location: 18 locations
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 17 locations
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Status: Active
Location: 19 locations